We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · June 15, 2021

ASCO 2021: HER2CLIMB Update Shows Benefits of Adding Tucatinib to Trastuzumab and Capecitabine Are Maintained in Metastatic Breast Cancer

With an additional 15.6 months of follow-up, overall and progression-free survival improvements remained

PracticeUpdate Editorial Team